The promise of in silico drug development to improve patient outcomes

In the last two years, pharmaceutical companies have become increasingly interested in the possibilities in silico technologies bring to the world’s multi-billion-dollar drug development market. Among the factors that have been reported as drivers of recent interest in what is also known as virtual clinical trials are the COVID-19-related restrictions that began impacting traditional human-based

Read moreā€¦

The promise of in silico drug development to improve patient outcomes originally appeared in KevinMD.com.

Read the full post on KevinMD.com